Table 2—

Clinical characteristics in the remission and nonremission groups

ItemRemissionNonremissionP
n3236
Age (years)50.6 ± 10.451.6 ± 13.10.718
BMI before CSII (kg/m2)25.9 ± 4.324.3 ± 3.10.069
BMI after CSII (kg/m2)26.0 ± 4.224.3 ± 3.00.051
HbA1c before CSII (%)10.3 ± 1.910.0 ± 1.90.647
HbA1c after CSII (%)9.2 ± 2.08.6 ± 1.50.207
FPG before CSII (mmol/l)14.9 ± 3.014.7 ± 5.00.852
FPG after CSII (mmol/l)6.1 ± 1.26.7 ± 1.1*0.035
PPBG before CSII (mmol/l)21.7 ± 5.119.7 ± 5.50.141
PPBG after CSII (mmol/l)8.8 ± 2.29.9 ± 2.40.064
Duration to achieve glycemic control (days)8.5 ± 3.18.8 ± 3.90.757
Maximal total daily insulin dose to achieve glycemic control (units/kg)0.7 ± 0.20.7 ± 0.20.744
LnHOMA-IR before CSII 2.3 ± 0.52.1 ± 0.50.117
LnHOMA-IR after CSII 1.3 ± 0.51.2 ± 0.50.456
LnHOMA-B before CSII 3.3 ± 0.63.2 ± 0.50.631
LnHOMA-B after CSII 4.8 ± 0.64.4 ± 0.7*0.002
AUC of insulin before CSII (pmol · l−1 · min−1)834.8 ± 352.3853.6 ± 365.40.837
AUC of insulin after CSII (pmol · l−1 · min−1)1,423.4 ± 523.21,159.5 ± 476.8*0.044
AUC of C-peptide before CSII (pmol · l−1 · min−1)7.0 ± 3.26.3 ± 3.40.384
AUC of C-peptide after CSII (pmol · l−1 · min−1)9.9 ± 4.37.8 ± 3.4*0.036
AIR before CSII (pmol · l−1 · min−1)−316.1 ± 214.9−152.2 ± 311.2*0.020
AIR after CSII (pmol · l−1 · min−1)326.45 ± 413.1255.2 ± 307.70.447
ΔAIR (pmol · l−1 · min−1)621.8 ± 430.4387.3 ± 428.8*0.033
  • Data are means ± SD.

  • *

    * P < 0.05 vs. the remission group;

  • HOMA-IR and HOMA-B were nonnormally distributed, so the data were logarithmically transformed before analysis. PPBG, postprandial plasma blood glucose.